Clinical trial
Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer
NCT00431054 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00431054 |
|---|---|
| Title | Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer |
| Official title | Pharmacodynamic Trial: Molecular Marker & Imaging Studies as Primary Endpoints to Determine Optimal Biological Dosage of Perifosine, Orally Avail AKT PH Domain Inhibitor Combined w/ Docetaxel in Patients w/Relapsed Epithelial Ovarian Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Keryx Biopharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | Perifosine, Docetaxel |
| Enrollment | 22 |
| Start date | Feb 1, 2007 |
| Primary completion | May 1, 2012 |
| Completion | May 1, 2012 |
| First posted | Feb 5, 2007 |
| Last update posted | Feb 19, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: